There are currently 14 ongoing clinical trials involving Post Polio Syndrome
Of the 14 trials,14 trials are in Phase II/III
Furthermore, 14 trials are in Phase II/III
The global pharmaceutical industry is steadily developing new drugs for Post Polio Syndrome, an Infectious Disease indication.
Grifols SA: The ongoing Post Polio Syndrome related clinical trial sponsor
Grifols SA is among the notable clinical trial sponsors involved in Post Polio Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Post Polio Syndrome
Aceglutamide, and Bendazole are among the key marketed drugs involving Post Polio Syndrome.
Aceglutamide is a psycho-stimulant agent. Aceglutamide is an psycho-stimulant agent. It is thought to act as a source of glutamine and prevents the nerve damage which aids in treating the nervous system diseases. It is formulated as powder for solution for intravenous and intramuscular route of administration. Aceglutamide is indicated for the treatment of traumatic brain coma, coma caused by neurosurgery, hepatic coma and hemiplegia, high paraplegia, sequelae of polio, neuropathic headache and low back pain. Aceglutamide is sold in China by Hainan Hualon Pharmaceutical Co Ltd.
Bendazole acts as an antihypertensive agent. It functions via Tubulin Inhibitor mechanism of action. It is formulated as tablets for oral route of administration. Bendazole is used in the treatment of mild hypertension, cerebral vasospasm, gastrointestinal smooth muscle spasm, post polio syndrome, peripheral facial nerve paralysis, post pregnancy hypertension syndrome. Bendazole is sold in China by Beijing Zhongxin Pharmaceutical Co Ltd.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward